Low Dose Melphalan and Bortezomib for AML and High-Risk MDS

Clinical trial NCT00789256 · COMPLETED

Trial details

NCT number: NCT00789256
Sponsor: Dartmouth-Hitchcock Medical Center
Status: COMPLETED
Phase: Not Applicable
Study type: INTERVENTIONAL

Acute Myelogenous Leukemia Myelodysplastic Syndromes

Start date: 2004-09-01
Primary completion: 2008-12-01
Enrollment: 26

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.